It is short of the dosage form specific l for children in China's market . rhIFNα 1b is the only interferon product approved by CFDA for pediatric clinical safety. It took Tri-Prime for 4 years to complete a Clinical study on the treatment of viral pneumonia in children with interferon alpha 1b inhalation. The result proved that this product is safe and tolerable in children.  A series of studies have been completed including virus sensitivity screening, tissue distribution, safety of aerosol inhalation, PK and PD  in animal, safety and tolerance in Children  and multi- center clinical research. The related references include patents (201110407386.4、201110407570.9、201110408121.6).